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ABSTRACT
Non-small cell lung cancers (NSCLCs) that harbor an oncogenic KRAS mutation are 
often associated with resistance to targeted therapies. The MUC1-C transmembrane 
protein is aberrantly overexpressed in NSCLCs and confers a poor outcome; however, 
the functional role for MUC1-C in mutant KRAS NSCLC cells has remained unclear. The 
present studies demonstrate that silencing MUC1-C in A549/KRAS(G12S) and H460/
KRAS(Q61H) NSCLC cells is associated with downregulation of AKT signaling and 
inhibition of growth. Overexpression of a MUC1-C(CQC→AQA) mutant, which inhibits 
MUC1-C homodimerization and function, suppressed both AKT and MEK activation. 
Moreover, treatment with GO-203, an inhibitor of MUC1-C homodimerization, blocked 
AKT and MEK signaling and decreased cell survival. The results further demonstrate 
that targeting MUC1-C suppresses expression of the ZEB1 transcriptional repressor 
by an AKT-mediated mechanism, and in turn induces miR-200c. In concert with these 
effects on the ZEB1/miR-200c regulatory loop, targeting MUC1-C was associated with 
reversal of the epithelial-mesenchymal transition (EMT) and inhibition of self-renewal 
capacity. Loss of MUC1-C function also attenuated KRAS independence and inhibited 
growth of KRAS mutant NSCLC cells as tumors in mice. These findings support a model 
in which targeting MUC1-C inhibits mutant KRAS signaling in NSCLC cells and thereby 
reverses the EMT phenotype and decreases self-renewal.
INTRODUCTION
Approximately 25% of patients with non-small 
cell lung cancer (NSCLC) harbor an oncogenic KRAS 
mutation that is often associated with resistance to 
conventional and targeted therapies [1]. NSCLC cells 
expressing activated KRAS are therefore potential targets 
for KRAS inhibitors. However, pharmacologic inhibition 
of mutant KRAS has not as yet proven successful, a 
situation that has necessitated a focus on therapeutic 
approaches using inhibitors of the downstream AKT and 
MEK pathways. In this context, concurrent inhibition of 
AKT and MEK signaling has been shown to be effective 
in inducing regressions of mutant Kras-driven murine 
lung adenocarcinomas [2] and this strategy is being 
evaluated for the treatment of patients with mutant KRAS 
NSCLC. Other potential targets for inhibiting growth 
of mutant KRAS NSCLC cells have been identified in 
synthetic lethal RNAi and drug screens. For example, 
the  non-canonical  IκB  kinase TBK1  and  downstream 
NF-κB signals are essential for survival of mutant KRAS 
NSCLC cells [3]. GATA2 and CDK4 have also been 
shown to be of importance for the growth and survival of 
NSCLC cells expressing mutant KRAS [4, 5]. In a small 
molecule screen, mutant KRAS NSCLC cells were more 
sensitive to inhibition of the RAF→MEK→ERK pathway 
as compared to KRAS wild-type cells [6]. By contrast, 
such selectivity for KRAS mutant cells was not observed Oncotarget 8894 www.impactjournals.com/oncotarget
with inhibitors of the PI3K→AKT→mTOR pathway [6]. 
Notably, not all NSCLC cells expressing mutant 
KRAS are dependent on KRAS for survival [7]. In this 
context, KRAS-dependent NSCLC cells exhibit a well-
differentiated phenotype, whereas KRAS-independent 
cells are associated with the epithelial-mesenchymal 
transition (EMT) [7]. Treatment of KRAS-dependent 
NSCLC cells with TGFβ1, an inducer of EMT, reduces 
dependence on KRAS, further indicating that EMT 
contributes to KRAS independence [7]. These findings 
and the demonstration that sensitivity of NSCLC cells to 
EGFR inhibitors is inhibited by EMT [8] have supported 
an association between EMT and loss of oncogene 
addiction.
Mucin 1 (MUC1) is a transmembrane heterodimeric 
protein that is aberrantly expressed in NSCLCs. Over 
80% of NSCLCs of the adenocarcinoma subtype express 
MUC1 at high levels [9]. In addition, the overexpression 
of MUC1 in NSCLC is associated with poor disease-
free and overall survival [9–13]. Of importance to 
understanding its function in NSCLC, MUC1 is translated 
as a single polypeptide that undergoes autocleavage 
into two subunits that, in turn, form a stable non-
covalent heterodimer at the cell surface [14]. The MUC1 
N-terminal subunit (MUC1-N) contains glycosylated 
tandem repeats that are characteristic of the mucin family. 
The MUC1 C-terminal subunit (MUC1-C) is a single-
pass transmembrane protein that interacts with receptor 
tyrosine kinases, such as EGFR and others [14]. Moreover, 
the MUC1-C 72 amino acid cytoplasmic tail contains 
multiple phosphorylation sites and interacts with diverse 
effectors that have been linked to transformation [14]. 
For example, MUC1-C contributes to activation of the 
canonical NF-κB pathway by constitutively interacting 
with the IκB kinase (IKK) complex in cancer cells and 
in the response to inflammatory cytokine stimulation of 
non-malignant epithelial cells [15]. MUC1-C also binds 
directly to NF-κB p65 and promotes NF-κB-mediated 
gene transcription [16]. The available evidence in breast 
cancer cells indicates that involvement of MUC1-C in 
NF-κB signaling is linked to the induction of EMT and 
self-renewal [17, 18]. In this way, MUC1-C occupies 
the ZEB1 promoter with NF-κB and thereby promotes 
ZEB1  transcription  [17].  In  turn,  MUC1-C  associates 
with ZEB1 and the MUC1-C/ZEB1 complex suppresses 
transcription of miR-200c, an inducer of epithelial 
differentiation [17]. MUC1-C also induces breast cancer 
cell sphere formation, a characteristic that is associated 
with EMT and self-renewing stem cells, by an NF-κB-
dependent mechanism [18]. To our knowledge, there is 
nothing known about involvement of MUC1-C in EMT or 
self-renewal of NSCLC cells. In addition, there have been 
no reports linking MUC1-C to KRAS addiction in lung or 
other cancer cells.
The overexpression of MUC1 in NSCLCs and other 
types of carcinomas has supported the attractiveness of 
MUC1-N and MUC1-C as potential cancer targets [19]. 
In this context, underglycosylation of the MUC1-N 
tandem repeats in tumor cells, as compared to normal 
epithelia, provided the basis for targeting MUC1-N 
with antibodies and vaccines [14]. Additionally, the 
oncogenic MUC1-C subunit contains a CQC motif in 
the cytoplasmic domain that is necessary and sufficient 
for MUC1-C homodimerization and function [20, 21]. 
Notably in this regard, expression of MUC1-C with 
mutation of the CQC motif to AQA blocks anchorage-
independent growth and tumorigenicity of cancer cells, 
consistent with a dominant-negative effect [20, 22]. 
Based on those observations, cell-penetrating peptides, 
such as GO-203, were developed to target the MUC1-C 
CQC motif and inhibit MUC1-C-mediated survival 
mechanisms [23, 24]. Accordingly, targeting MUC1-C 
in cancer cells is achievable by several approaches that 
include (i) silencing with shRNAs, (ii) expression of the 
MUC1-C(CQC→AQA) mutant, and (iii) treatment with 
GO-203. Using these approaches, the present studies 
demonstrate that MUC1-C is of functional importance to 
KRAS dependency in NSCLC cells that harbor activating 
KRAS mutations. The results show that MUC1-C drives 
EMT and thereby confers stemness. Targeting MUC1-C 
thus reverses EMT and inhibits self-renewal in mutant 
KRAS NSCLC cells.
RESULTS
Silencing MUC1-C suppresses AKT in NSCLC 
cells with activating KRAS mutations
Human A549 NSCLC cells harbor the KRAS(G12S) 
mutation [25]. To assess the potential involvement of 
MUC1-C in activated KRAS signaling, A549 cells were 
infected with lentiviruses expressing a control CshRNA 
or one targeting MUC1-C (MUC1shRNA) (Fig. 1A). 
In A549/MUC1shRNA  cells,  we  found  that  silencing 
MUC1-C results in decreased phosphorylation of AKT 
and the downstream effector S6K (Fig. 1B, left), but has 
no apparent effect on MEK and ERK activation (Fig. 1B, 
right). Silencing MUC1-C was also associated with a 
slowing of cell growth (Fig. 1C). To extend this analysis, 
H460/KRAS(Q61H) NSCLC cells were infected to stably 
express the CshRNA or MUC1shRNA (Fig. 1D). H460 
cells similarly responded to downregulation of MUC1-C 
with suppression of AKT and S6K activation (Fig. 1E, 
left). Moreover, p-MEK and p-ERK levels were increased, 
consistent  with  a  potential  compensatory  feedback 
response to decreases in AKT activity (Fig. 1E, right). 
As found for A549 cells, silencing MUC1-C resulted in 
inhibition of H460 cell growth (Fig. 1F).Oncotarget 8895 www.impactjournals.com/oncotarget
Targeting MUC1-C inhibits AKT and MEK 
signaling in KRAS mutant NSCLC cells
The MUC1-C subunit includes a 72 amino acid (aa) 
cytoplasmic domain with a CQC motif that is necessary 
and sufficient for MUC1-C homodimerization (Fig. 2A) 
[14]. Expression of MUC1-C with mutation of the CQC 
motif to AQA acts as a dominant-negative of MUC1-C 
function [22]. Accordingly, MUC1-C or MUC1-C(AQA) 
was stably overexpressed in A549 cells to assess the effects 
of the mutant (Fig. 2B, left). As found with MUC1-C 
silencing, overexpression of MUC1-C(AQA) was 
associated with suppression of AKT and S6K activation 
(Fig. 2B, right). In addition and in contrast to silencing 
MUC1-C, expression of MUC1-C(AQA) resulted in 
downregulation of MEK→ERK activation (Fig. 2B, right). 
MUC1-C(AQA) also inhibited A549 cell growth (Fig. 2C). 
The MUC1-C inhibitor, GO-203, is a cell penetrating 
peptide that contains a poly-Arg transduction domain 
linked to CQCRRKN (Fig. 2A). GO-203 blocks MUC1-C 
homodimerization and thereby its oncogenic function 
[21, 24]. Treatment of A549 cells with GO-203 was 
associated with transient downregulation of p-AKT levels 
at 3–9 h and then reactivation at 24 h (Fig. 2D, left and 
Figure 1: Silencing MUC1-C downregulates AKT and inhibits NSCLC cell growth. (A) A549 cells were stably infected 
with lentiviruses expressing a control scrambled shRNA (CshRNA) or a MUC1 shRNA. Lysates were immunoblotted with the indicated 
antibodies. (B) Lysates from A549/CshRNA and A549/MUC1shRNA cells were immunoblotted with the indicated antibodies. (C) A549/
CshRNA and A549/MUC1shRNA cells were plated at 5 × 104 cells/well. The results (mean±SD of three replicates) are expressed as cell 
number on day 4. (D) H460 cells were stably infected with lentiviruses expressing CshRNA or MUC1shRNA. Lysates were immunoblotted 
with the indicated antibodies. (E) Lysates from H460/CshRNA and H460/MUC1shRNA cells were immunoblotted with the indicated 
antibodies. (F) H460/CshRNA and H460/MUC1shRNA cells were plated at 5 × 104 cells/well. The results (mean±SD of three replicates) 
are expressed as cell number on day 4.Oncotarget 8896 www.impactjournals.com/oncotarget
right). Retreatment with GO-203 at 24 h resulted in further 
suppression of AKT activation at 48 h (Fig. 2D, left and 
right). Moreover and like MUC1-C(AQA), we found that 
GO-203 inhibits MEK→ERK activation (Fig. 2D, left 
and right). GO-203 was also highly effective in inhibiting 
survival of A549 cells (Fig. 2E). By contrast, treatment 
with a control peptide CP-2 (Fig. 2A), that is inactive in 
inhibiting MUC1-C [21], had no effect on (i) AKT activity 
(Supplemental Fig. S1A) or (ii) loss of clonogenic survival 
(Fig. 2E). As confirmation of these findings, treatment of 
H460 cells with GO-203, but not CP-2 (Supplemental 
Fig. S1B), was similarly associated with suppression of 
AKT and MEK/ERK signaling (Supplemental Fig. S2A) 
and loss of survival (Supplemental Fig. S2B).
Silencing MUC1-C suppresses ZEB1 expression
A549 and H460 cells exhibit an EMT phenotype, 
which is a characteristic of importance for KRAS 
independence [7]. To determine if MUC1-C regulates 
EMT in these NSCLC cells, we first studied the effects 
of  silencing  MUC1-C  on  expression  of  the  ZEB1 
transcription factor and inducer of the mesenchymal 
phenotype [26]. Downregulation of MUC1-C in A549 
cells was associated with marked suppression of ZEB1 
levels  (Fig.  3A).  In  H460  cells,  ZEB1  expression 
was also decreased in response to MUC1-C silencing 
(Fig. 3B). In addition, we found that silencing MUC1-C 
suppresses ZEB1 mRNA levels in A549 and H460 cells 
Figure 2: Targeting MUC1-C function suppresses AKT and MEK→ERK signaling. (A) Schema of the MUC1-C subunit 
with the 58 aa extracellular domain (ED), 28 aa transmembrane domain (TM) and sequence of the 72 aa cytoplasmic domain (CD). The 
CQC motif is necessary for MUC1-C homodimerization and is the target for GO-203 treatment. Also highlighted are the binding sites that 
link the MUC1-C cytoplasmic domain to activation of the PI3K→AKT and MEK→ERK pathways. (B) A549 cells were stably transfected 
with vectors expressing MUC1-C or the MUC1-C(CQC→AQA) mutant [designated MUC1-C(AQA)]. Lysates were immunoblotted with 
the indicated antibodies. (C) A549/MUC1-C and A549/MUC1-C(AQA) cells were plated at 5 × 104 cells/well. The results (mean±SD 
of three replicates) are expressed as cell number on day 4. (D) A549 cells were treated with 5 μM GO-203 at 0 and 24 h. Lysates were 
immunoblotted with the indicated antibodies (left and right). (E) A549 cells were seeded at 1000 cells/well in 6-well plates and left 
untreated (Control) or treated with 5 μM GO-203 or 5 μM CP-2 each day for 4 days. Colonies were stained with crystal violet on day 15 
after treatment (left). Colony number (>30 cells) is expressed as the mean±SD of three replicates (right).Oncotarget 8897 www.impactjournals.com/oncotarget
(Figs. 3C and D), consistent with involvement of 
MUC1-C in upregulating ZEB1 transcription. In 
contrast to the KRAS-independent A549 and H460 
cells and consistent with previous observations [7], 
there was no detectable ZEB1 expression in the KRAS-
dependent H358 and H441 cells (data now shown). 
Activation of AKT has been linked to the induction 
of ZEB1 expression [27, 28]. In concert with those 
observations and the demonstration that targeting 
MUC1-C suppresses AKT and ZEB1, we found that 
inhibiting AKT with GSK690693 is associated with 
downregulation  of  ZEB1  in  A549  and  H460  cells 
(Figs. 3E and F). Moreover and consistent with ZEB1-
mediated suppression of miR-200c [26], we found that 
silencing MUC1-C is associated with induction of miR-
200c levels (Figs. 3G and H). These findings provided 
support for a model in which MUC1-C contributes to the 
activation of AKT and thereby the coordinate induction 
of ZEB1 and suppression of miR-200c expression.
Silencing MUC1-C reverses EMT and KRAS 
independence
miR-200c is an inducer of epithelial 
differentiation [26]. Thus, with the suppression of ZEB1 
and induction of miR-200c, silencing MUC1-C in A549 
cells was associated with upregulation of E-cadherin, and 
decreases in N-cadherin and vimentin, consistent with 
reversal of EMT (Fig. 4A). In H460 cells, E-cadherin was 
not detectable in the absence or presence of MUC1-C 
silencing. However, downregulation of MUC1-C resulted 
in decreased expression of N-cadherin and vimentin 
(Fig. 4B). Similar results were obtained when A549 and 
H460 cells were treated with the AKT inhibitor, linking 
suppression of AKT to the reversal of EMT (Figs. 4C 
and D). In addition, to confirm that the downregulation 
of  ZEB1  in  response  to  MUC1-C  silencing  is  also 
responsible for reversing EMT, we silenced ZEB1 and 
found induction of the mesenchymal-epithelial transition 
Figure 3: Silencing MUC1-C confers the coordinate downregulation of ZEB1 and induction of miR-200c expression. 
(A and B) Lysates from A549 (A) and H460 (B) cells expressing CshRNA or MUC1shRNA were immunoblotted with the indicated 
antibodies. (C and D) ZEB1 mRNA levels for the indicated A549 (C) and H460 (D) cells were determined by qRT-PCR. The results are 
expressed as relative ZEB1 mRNA levels (mean±SD of three determinations) as compared to that obtained for GAPDH as a control. 
(E and F) A549 (E) and H460 (F) cells were left untreated or treated with 10 μM GSK690693 for 48 h. Lysates were immunoblotted 
with the indicated antibodies. (G and H) Relative miR-200c levels in the indicated A549 (G) and H460 (H) cells were determined by 
qRT-PCR. The results are expressed as relative miR-200c levels (mean±SD of three determinations) as compared to that obtained for 
U6 as a control.Oncotarget 8898 www.impactjournals.com/oncotarget
(MET) as evidenced by decreases in N-cadherin and 
vimentin  (Figs.  4E  and  F).  EMT  has  been  linked  to 
KRAS independence in mutant KRAS NSCLC cells [7]. 
Accordingly, we asked if silencing MUC1-C converts 
KRAS independence to dependence on KRAS for 
survival. Indeed, the downregulation of KRAS in A549/
MUC1shRNA cells was associated with increases in 
caspase-3 cleavage (Fig. 4G, left) and cell death (Fig. 4G, 
right) as compared to that obtained for A549/CshRNA 
cells. Similar results were obtained in studies of H460/
CshRNA and H460/MUC1shRNA cells with suppression 
of KRAS expression (Fig. 4H, left and right), indicating 
that MUC1-C contributes to KRAS independence.
Targeting MUC1-C function induces MET
As noted above and in addition to MUC1-C 
silencing, we studied the effects of targeting MUC1-C 
function on EMT by (i) stable expression of the MUC1-
C(AQA) mutant, and (ii) treatment with the MUC1-C 
inhibitor GO-203. Overexpression of MUC1-C(AQA) 
in A549 cells was associated with decreases in ZEB1 
(Fig. 5A, left and right) and upregulation of miR-200c 
expression  (Fig.  5B).  In  addition,  the  A549/MUC1-
C(AQA) cells exhibited reversal of EMT, as evidenced 
by increases in E-cadherin and suppression of N-cadherin 
and vimentin (Fig. 5C). Treatment of A549 cells with   
GO-203 also decreased ZEB1 mRNA and increased miR-
200c levels (Figs. 5D and E). Moreover, GO-203 treatment 
was associated with the acquisition of an epithelial 
phenotype (Fig. 5F). Thus, inhibition of MUC1-C 
function with different approaches supported the notion 
that MUC1-C drives EMT in mutant KRAS NSCLC cells.
MUC1-C promotes self-renewal
Sphere formation under non-adherent growth 
conditions selects for the expansion of self-renewing 
cancer  stem-like  cells  (CSCs),  which  survive  anoikis 
[29, 30]. Silencing MUC1-C had little effect on the size 
of A549 spheres (Fig. 6A, left). However, downregulation 
of MUC1-C expression significantly decreased the sphere 
Figure 4: Silencing MUC1-C reverses EMT and KRAS independence. (A and B) Lysates from A549 (A) and H460 (B) cells 
expressing CshRNA or MUC1shRNA were immunoblotted with the indicated antibodies. (C and D) A549 and H460 cells were left 
untreated or treated with 10 μM GSK690693 for 48 h. Lysates were immunoblotted with the indicated antibodies. (E and F) Lysates from 
A549 (E) and H460 (F) cells expressing CshRNA or MUC1shRNA were immunoblotted with the indicated antibodies. (G and H) A549/
CshRNA and A549/MUC1shRNA (G) or H460/CshRNA and H460/MUC1shRNA (H) cells were infected twice over 24 h with lentivirus 
expressing a KRAS shRNA. At 48 h post-infection, cells were (i) collected for immunoblotting with the indicated antibodies (left) or 
(ii) plated at a density of 5 × 104 in a 6-well plate. The results (mean±SD of three replicates) are expressed as percent cell death as 
determined by trypan blue exclusion on day 4 (right).Oncotarget 8899 www.impactjournals.com/oncotarget
forming  efficiency  (%SFE)  of  A549  cells  (Fig.  6A, 
right). Similar results were obtained when studying 
A549 cells expressing the MUC1-C(AQA) mutant 
(Fig. 6B). Treatment of A549 cells with GO-203, but not   
CP-2,  blocked  sphere  formation  (Fig.  6C,  left  and 
right). Moreover, when A549 spheres were established 
and then treated with peptide, GO-203 was effective in 
disrupting the spheres, whereas CP-2 had little if any 
effect (Fig. 6D, left and right). In studies of H460 cells, 
we also found that (i) MUC1-C silencing (Fig. 6E, left 
and right) and (ii) GO-203 treatment (Fig. 6F, left and 
right) are associated with suppression of sphere formation. 
In addition, GO-203 was effective in conferring the 
disruption of established H460 spheres (Fig. 6G, left and 
right). These results provided support for the involvement 
of MUC1-C in self-renewal of A549 and H460 cells.
KRAS mutant NSCLC tumorigenicity is  
MUC1-C-dependent
To  extend  the  findings  that  MUC1-C  promotes 
self-renewal, we investigated the effects of silencing 
MUC1-C on tumorigenicity of A549 cells. Consistent 
with the decreased capacity for sphere formation, growth 
of A549/MUC1shRNA cells was significantly inhibited as 
compared to that found for A549/CshRNA cells (Fig. 7A). 
As found in in vitro studies, immunoblot analysis of the 
A549 tumors further showed that MUC1-C silencing is 
associated with downregulation of ZEB1, increases in 
E-cadherin, and decreases in N-cadherin and vimentin 
(Fig. 7B). Growth of H460 cells as tumor xenografts 
was also slowed as a consequence of MUC1-C silencing 
(Fig.  7C).  Moreover,  the  H460/MUC1shRNA  tumors 
Figure 5: Targeting MUC1-C induces MET. (A) Lysates from A549/MUC1-C and A549/MUC1-C(AQA) cells were immunoblotted 
with the indicated antibodies (left). ZEB1 mRNA levels were determined by qRT-PCR. The results are expressed as relative ZEB1 mRNA 
levels (mean±SD of three determinations) as compared to that obtained for GAPDH as a control (right). (B) miR-200c levels in A549/
MUC1-C and A549/MUC1-C(AQA) cells were determined by qRT-PCR. The results are expressed as relative miR-200c levels (mean±SD 
of three determinations) as compared to that obtained for U6 as a control. (C) Lysates from A549/MUC1-C and A549/MUC1-C(AQA) were 
immunoblotted with the indicated antibodies. (D) A549 cells were left untreated or treated with 5 μM GO-203 for 48 h. ZEB1 mRNA levels 
were determined by qRT-PCR. The results are expressed as relative ZEB1 mRNA levels (mean±SD of three determinations) as compared to 
that obtained for GAPDH as a control. (E) A549 cells were left untreated or treated with 5 μM GO-203 for 48 h. Relative miR-200c levels 
were determined by qRT-PCR. The results are expressed as relative miR-200c levels (mean±SD of three determinations) as compared to 
that obtained for U6 as a control. (F) A549 cells were left untreated or treated with 5 μM GO-203 for 48 h. Lysates were immunoblotted 
with the indicated antibodies.Oncotarget 8900 www.impactjournals.com/oncotarget
exhibited decreases in ZEB1, N-cadherin and vimentin, 
consistent with the MET phenotype (Fig. 7D).
DISCUSSION
Targeting mutant KRAS in NSCLC and other 
types of tumors with small molecule inhibitors has been 
unsuccessful to date [1]. Therapeutic approaches have 
therefore focused on the downstream AKT and MEK 
pathways which can confer dependence on mutant 
KRAS for survival [1]. The MUC1-C oncoprotein is 
aberrantly expressed in NSCLC and is associated with 
poor clinical outcomes [12, 13]; however, little was 
known about whether MUC1-C contributes to mutant 
KRAS signaling. To address this issue, we used three 
strategies to inhibit MUC1-C function and thereby 
assess effects on the KRAS downstream AKT and MEK 
pathways. Consistent with a direct interaction between 
the MUC1-C cytoplasmic domain and PI3K [24, 31], we 
found that silencing MUC1-C NSCLC cells harboring 
mutant KRAS is associated with downregulation of the 
AKT pathway, but has no apparent effect on MEK→ERK 
signaling. The MUC1-C oncogenic function is dependent 
on the formation of MUC1-C homodimers through 
a CQC motif in the cytoplasmic domain [14, 32]. 
Interestingly and as a second approach, stable expression 
of  a  MUC1-C(CQC→AQA)  mutant,  which  acts  as  a 
dominant-negative of MUC1-C function [22], resulted 
Figure 6: MUC1-C is necessary for self-renewal. (A and B) Representative images are shown for the indicated A549 cells plated at 
2000 cells/well and grown for 5 days in sphere culture (left). Bar represents 100 microns. The percentage SFE is expressed as the mean±SD 
of three determinations (right). (C) A549 cells were plated at 2000 cells/well in sphere culture and left untreated (Control) or treated with 
5 μM GO-203 or CP-2 for 3 days. Representative images on day 5 are shown for the indicated A549 cells (left). The percentage SFE is 
expressed as the mean±SD of three determinations (right). (D) A549 cells were plated at 2000 cells/well and cultured for 5 days. The 
established spheres were then left untreated (Control) or treated with 5 μM GO-203 or CP-2 for 3 days. Representative images are shown 
for the indicated A549 cells (left). The percentage SFE is expressed as the mean±SD of three determinations (right). (E) Representative 
images are shown for the indicated H460 cells plated at 1500 cells/well and grown for 5 days in sphere culture (left). Bar represents 
100 microns. The percentage SFE is expressed as the mean±SD of three determinations (right). (F) H460 cells were plated at 1500 cells/
well in sphere culture and left untreated (Control) or treated with 5 μM GO-203 or CP-2 for 3 days. Representative images on day 5 are 
shown for the indicated H460 cells (left). The percentage SFE is expressed as the mean±SD of three determinations (right). (G) H460 cells 
were plated at 1500 cells/well and cultured for 5 days. The established spheres were then left untreated (Control) or treated with 5 μM 
GO-203 or CP-2 for 3 days. Representative images are shown for the indicated H460 cells (left). The percentage SFE is expressed as the 
mean±SD of three determinations (right).Oncotarget 8901 www.impactjournals.com/oncotarget
Figure 7: MUC1-C promotes mutant KRAS NSCLC cell tumorigenicity.  (A)  A549/CshRNA  (squares)  and  A549/ 
MUC1shRNA (circles) cells (4 × 106) were injected subcutaneously in the flanks of female nude mice. Tumor volumes were determined on 
the indicated days after injection. The results are expressed as tumor volumes (mean±SEM for 3 mice). The asterisk denotes a significant 
difference (p=0.02) between growth of the A549/CshRNA and A549/MUC1shRNA tumors on day 38. (B) Lysates from tumors isolated on 
day 30 from mice in the different treatment groups were immunoblotted with indicated antibodies. (C) H460/CshRNA (squares) and H460/
MUC1shRNA (triangles) cells (4 × 106) were injected subcutaneously in the flanks of female nude mice. Tumor volumes were determined 
on the indicated days after injection. The results are expressed as tumor volumes (mean±SEM for 3 mice). The asterisk denotes a significant 
difference (p=0.013) between growth of the H460/CshRNA and H460/MUC1shRNA tumors on day 13. (D) Lysates from tumors isolated 
on day 13 from mice in the different treatment groups were immunoblotted with indicated antibodies. (E) Schema depicting the proposed 
pathway in which MUC1-C activates AKT and thereby the coordinate induction of ZEB1 and suppression of miR-200c. In turn, MUC1-C 
drives EMT, self-renewal and KRAS independence.
in suppression of both AKT and MEK. As a third 
approach, treatment with the GO-203 inhibitor, which 
binds to the MUC1-C CQC site and blocks MUC1-C 
homodimerization, also suppressed both AKT and MEK 
activity. In contrast to targeting the MUC1-C CQC motif 
with the MUC1-C(AQA) mutant or GO-203, the absence 
of MEK downregulation in response to stable MUC1-C 
silencing may represent a compensatory response to 
suppression of AKT, as has been observed in other settings 
[33]. Nonetheless, our results demonstrate that inhibiting 
MUC1-C in several different ways is associated with 
suppression of key pathways that reside downstream of 
mutant KRAS and are necessary for growth and survival.
Concurrent inhibition of the AKT and MEK 
pathways in a murine lung adenocarcinoma model driven 
by mutant Kras  is  associated  with  significant  tumor 
regressions [2]. The precise mechanisms responsible for 
mutant KRAS cell death in response to inhibiting AKT 
and MEK signaling remain unclear; however, several 
studies indicate that these pathways converge in the 
regulation of MYC expression [34]. In this way, MYC 
has been shown to be of importance for the survival of Oncotarget 8902 www.impactjournals.com/oncotarget
cells with activated KRAS [35]. The present studies do 
not exclude the possibility that MUC1-C can contribute 
to the regulation of MYC in mutant KRAS NSCLC cells 
and therefore further studies will be needed to address 
this possibility. From a mechanistic standpoint, NSCLC 
cells with activated KRAS can vary in their dependency 
on KRAS [7, 36]. Engagement of the AKT and MEK 
pathways, and sensitivity to their respective inhibitors, are 
not a function of KRAS dependency [7]. Rather, extent 
of KRAS dependency appears to reside in downstream 
regulation of EMT [7]. Notably in this regard, recent 
studies have shown that MUC1-C induces EMT in 
breast cancer cells by the upregulation of ZEB1 and the 
coordinate suppression of miR-200c [17]. In the present 
studies, silencing MUC1-C in NSCLC cells decreased 
ZEB1, which in turn was associated with increases in miR-
200c, and significantly, reversal of the EMT phenotype. 
The demonstration that targeting MUC1-C with the 
MUC1-C(AQA) mutant or GO-203 resulted in similar 
responses, providing support for the notion that MUC1-C 
is necessary for driving ZEB1 and thereby EMT in these 
NSCLC cells. AKT has been shown to contribute to the 
induction of ZEB1 expression [27, 28]. In concert with the 
involvement of AKT, we also found that inhibition of AKT 
suppressed ZEB1 expression. These findings thus support 
a model in which targeting MUC1-C downregulates 
AKT and thereby ZEB1 expression by an AKT-mediated 
mechanism (Fig. 7E).
The  coordinate  upregulation  of  ZEB1  and 
suppression of miR-200c, an inducer of epithelial 
differentiation, is associated with the induction of 
EMT [26]. Accordingly, we found that targeting MUC1-C 
with  the  downregulation  of  ZEB1  and  induction  of 
miR-200c resulted in MET, indicating that MUC1-C 
is necessary for conferring the EMT phenotype in these 
KRAS-independent NSCLC cells (Fig. 7E). Notably, EMT 
dictates the dependency of NSCLC cells on activated 
KRAS  [7].  By  extension,  silencing  MUC1-C  with 
reversal of EMT was associated with an increase in the 
KRAS dependency index. Similar enhancement of KRAS 
dependency was observed when targeting MUC1-C with 
the MUC1-C(AQA) mutant and GO-203, indicating that 
MUC1-C dictates EMT and KRAS dependency (Fig. 7E). 
EMT has been linked to cancer stem-like cells that have 
been characterized by the endowment of mesenchymal 
traits necessary for invasion and metastases [37]. In this 
way, EMT promotes the capacity to form spheres in 
non-adherent serum-free culture, a characteristic that is 
dependent on the presence of self-renewing stem-like cells 
[29, 30]. Therefore, the finding that MUC1-C confers the 
EMT phenotype in KRAS mutant NSCLC cells invoked 
the possibility that this observation could extend to self-
renewal (Fig. 7E). Indeed, we found that targeting MUC1-C 
with silencing or expression of the MUC1-C(CQC→AQA) 
mutant decreased sphere forming efficiency. Disruption of 
established spheres with the GO-203 inhibitor further 
demonstrated  that  these  KRAS  mutant  stem-like  cells 
are dependent on MUC1-C for their self-renewal. The 
involvement of MUC1-C in the capacity for self-renewal 
is further supported by the demonstration that silencing 
MUC1-C substantially decreases tumorigenicity of KRAS 
mutant NSCLC cells growing in nude mice. The available 
evidence indicates that cancer stem-like cells maintain 
low levels of reactive oxygen species (ROS) and that 
disruption of ROS defense mechanisms results in loss of 
self-renewal [38–41]. In this context, MUC1-C protects 
cells from increases in ROS associated with exposure to 
oxidative stress, hypoxia and glucose deprivation [32]. 
These observations and the sensitivity of cancer stem-like 
cells to disruption of redox balance lend credence to the 
possibility that MUC1-C is necessary for maintenance of 
ROS levels and thereby self-renewal.
Finally, the present work has focused on MUC1-C 
function in mutant KRAS-independent NSCLC cells 
that  express  ZEB1  and  exhibit  the  EMT  phenotype. 
Further studies will be needed to assess the role of 
MUC1-C in mutant KRAS-dependent NSCLC cells that 
are ZEB1 negative and exhibit epithelial characteristics. 
Nonetheless, the present findings indicate that targeting 
MUC1-C could be an effective therapeutic approach for 
at least certain mutant KRAS NSCLCs. In this respect, 
GO-203 has completed Phase I evaluation in patients 
with refractory solid tumors and a maximum tolerated 
dose has been identified for Phase II trials. Given the 
challenges being encountered in the treatment of mutant 
KRAS NSCLCs, our results lend support to the notion that 
targeting MUC1-C with GO-203 could be an alternative 
approach for these patients.
METHODS
Cell culture
Human A549/KRAS(G12S), H460/KRAS(Q61H), 
H358/KRAS(G12C)  and  H441/KRAS(G12V)  NSCLC 
cells (ATCC) were grown in RPMI1640 media 
supplemented with 10% heat-inactivated fetal bovine 
serum (HI-FBS), 100 μg/ml streptomycin, 100 units/ml   
penicillin and 2 mM L-glutamine. Authenticity of the 
cells was confirmed by short tandem repeat (STR) DNA 
profiling  (Dana-Farber  Cancer  Institute,  Molecular 
Biology Core). Cells were infected with lentiviral vectors 
expressing a MUC1 shRNA (Sigma), a scrambled control 
shRNA (CshRNA; Sigma) or a KRAS shRNA (Sigma). 
Cells were also transfected to stably express a control 
pHR-CMV vector expressing MUC1-C or one expressing 
MUC1-C(CQC→AQA).  Cells  were  treated  with  the 
MUC1-C inhibitor peptide GO-203, a control peptide 
CP-2 [24] or with the AKT inhibitor GSK690693 (Selleck 
Chemicals).Oncotarget 8903 www.impactjournals.com/oncotarget
Immunoblot analysis
Cell lysates were prepared as described [23]. The 
lysates were analyzed by immunoblotting with anti-
MUC1-C [42], anti-p-AKT, anti-AKT, anti-p-S6K, 
anti-S6K,  anti-p-MEK(Ser-217/221),  anti-MEK,  anti-
p-ERK(Thr-202/Tyr-204),  anti-ERK  (Cell  Signaling 
Technologies), anti-β-actin (Sigma), anti-KRAS (Santa 
Cruz Biotechnology) or anti-caspase-3 (Cell Signaling 
Technologies) as described [24, 43]. Immune complexes 
were detected with horseradish peroxidase-conjugated 
secondary antibodies and enhanced chemiluminescence 
(GE Healthcare).
Colony formation assays
Cells were seeded in 6-well plates for 24 h and then 
left untreated or treated with inhibitor. After 7–14 d, the 
cells were washed and stained with 0.5% crystal violet 
in 25% methanol. Colonies >30 cells were counted in 
triplicate wells.
Quantitative RT-PCR
cDNA synthesis was performed with 1 μg of total 
RNA using the Thermoscript RT-PCR assay system 
(Invitrogen). The cDNA samples were diluted and 
amplified using the SYBR green qPCR assay kit (Applied 
Biosystems) and the ABI Prism 7000 Sequence Detector 
(Applied  Biosystems).  Primers  used  for  ZEB1  and 
glyceraldehyde 3-phosphate dehydrogenase have been 
previously reported [17].
Analysis of miR-200c
RNA was isolated using the miRNeasy kit (Qiagen). 
cDNAs were prepared from 1 μg RNA using the cDNA 
synthesis  for  small  RNAs  (System  Biosciences).   
miR-200c was detected using a specific forward primer 
and a universal reverse primer as described [17]. Human 
U6 small RNA was used as a control [17]. The SYBR 
green qPCR assay kit (Applied Biosystems) was used with 
1 μl of diluted cDNA sample and analyzed with the ABI 
Prism 7000 Sequence Detector (Applied Biosystems).
Tumor spheres
NSCLC cells were harvested with gentle 
trypsinization, washed and resuspended in MammoCult™ 
Human Medium (Stem Cell Technologies). Single cells 
were  confirmed  under  a  microscope,  counted,  seeded 
in 6-well ultralow attachment culture plates (Corning 
CoStar) and cultured for 5 days. Tumor spheres of   
≥100  μm  were  visualized  and  scored  using  a  Nikon 
inverted TE2000 microscope. Sphere forming efficiency 
(SFE) was calculated by dividing the number of tumor 
spheres by the number of suspended cells.
NSCLC xenograft models
Four-  to  6-week  old  BALB/c  nu/nu  mice  were 
injected subcutaneously with 4 × 106 cells in the flank. 
Tumor volumes were calculated using the formula V=L2 × 
W/2, where L and W are the larger and smaller diameters, 
respectively.
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